Cargando…

Minimal Change Disease: More Than a Podocytopathy?

Detalles Bibliográficos
Autores principales:	Maas, Rutger J., Nijenhuis, Tom, van der Vlag, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039900/ https://www.ncbi.nlm.nih.gov/pubmed/35497782 http://dx.doi.org/10.1016/j.ekir.2022.03.001

Ejemplares similares

Delayed Onset Minimal Change Disease as a Manifestation of Lupus Podocytopathy
por: Aly, Rasha, et al.
Publicado: (2021)

Podocytopathy
por: Agarwal, Sanjay K.
Publicado: (2016)

Novel mouse strains to study circulating permeability factor(s) in primary focal segmental glomerulosclerosis
por: den Braanker, Dirk, et al.
Publicado: (2022)

Mycophenolate mofetil and telmisartan for the treatment of proteinuria secondary to minimal change disease podocytopathy in a dog
por: Travail, Victoria, et al.
Publicado: (2022)

Commentary: Minimally invasive surgery: More than meets the eye
por: Paul, Subroto
Publicado: (2020)

A Putative Role for TRPC6 in Immune-Mediated Kidney Injury
por: ‘t Hart, Daan C., et al.
Publicado: (2023)

Laminar flow substantially affects the morphology and functional phenotype of glomerular endothelial cells
por: ‘t Hart, Daan C., et al.
Publicado: (2021)

Repurposing Riociguat to Target a Novel Paracrine Nitric Oxide-TRPC6 Pathway to Prevent Podocyte Injury
por: ‘t Hart, Daan, et al.
Publicado: (2021)

Thrombotic microangiopathy triggered by podocytopathy
por: Veríssimo, Rita, et al.
Publicado: (2021)

Nephron Number as Predictor of Corticosteroid Response in Adult Minimal Change Disease
por: Van den Berge, Bartholomeus T., et al.
Publicado: (2020)

Titin–N2A: More than a signaling node?
por: van der Pijl, Robbert J., et al.
Publicado: (2021)

Commentary on “Comparison of minimally invasive and open TLIF outcomes with more than seven years of follow-up”
por: Smith-Voudouris, Julian, et al.
Publicado: (2022)

Adrenocorticotropic hormone analog use for podocytopathies
por: Filippone, Edward J, et al.
Publicado: (2016)

An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine
por: Maas, Rutger J., et al.
Publicado: (2021)

Defining diagnostic trajectories in patients with podocytopathies
por: Cirillo, Luigi, et al.
Publicado: (2022)

Modeling Podocyte Ontogeny and Podocytopathies with the Zebrafish
por: Drummond, Bridgette E., et al.
Publicado: (2023)

Primary Podocytopathies After COVID-19 Vaccination
por: Timmermans, Sjoerd A.M.E.G., et al.
Publicado: (2021)

Why illness is more important than disease in old age
por: Olde Rikkert, Marcel G M, et al.
Publicado: (2022)

Commentary: Rare eye diseases: More than meets the eye!
por: Jayadev, Chaitra, et al.
Publicado: (2022)

Vasopressin and ischaemic heart disease: more than coronary vasoconstriction?
por: Asfar, Pierre, et al.
Publicado: (2009)

Chronic obstructive pulmonary disease: More than meets the eye
por: Hatipoğlu, Umur
Publicado: (2018)

The Pathology Lesion Patterns of Podocytopathies: How and why?
por: Ravaglia, Fiammetta, et al.
Publicado: (2022)

The Role of Parietal Epithelial Cells in the Pathogenesis of Podocytopathy
por: Li, Zhi-hang, et al.
Publicado: (2022)

Mitochondrial Oxidative Stress and Cell Death in Podocytopathies
por: Zhu, Yu-Ting, et al.
Publicado: (2022)

Pathogenic Role of MicroRNA Dysregulation in Podocytopathies
por: Liu, Feng, et al.
Publicado: (2022)

Genes and Podocytes – New Insights into Mechanisms of Podocytopathy
por: Bierzynska, Agnieszka, et al.
Publicado: (2015)

Pathology of Podocytopathies Causing Nephrotic Syndrome in Children
por: Ranganathan, Sarangarajan
Publicado: (2016)

Understanding podocytopathy and its relevance to clinical nephrology
por: Singh, L., et al.
Publicado: (2015)

Compensation in the course of Huntington's disease — More than just a hypothesis?
por: Schiefer, Johannes
Publicado: (2015)

More Than Two HANDs to Tango
por: Kolson, Dennis, et al.
Publicado: (2013)

Siderophores: More than Stealing Iron
por: Behnsen, Judith, et al.
Publicado: (2016)

Expanding on the multidisciplinary stakeholder framework to minimize harms for problematic risk-taking involving emerging technologies. •: Commentary on: Problematic risk-taking involving emerging technologies: A stakeholder framework to minimize harms (Swanton et al., 2019)
por: Shi, Jing, et al.
Publicado: (2020)

Is there more to glycaemic control than meets the eye?
por: Chase, J Geoffrey, et al.
Publicado: (2007)

Sex differences in rheumatoid arthritis: more than meets the eye...
por: van Vollenhoven, Ronald F
Publicado: (2009)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

A Compendium of Urinary Biomarkers Indicative of Glomerular Podocytopathy
por: Sekulic, Miroslav, et al.
Publicado: (2013)

Recurrent podocytopathy in a patient with systemic lupus erythematosus
por: Paramalingam, Shereen, et al.
Publicado: (2017)

Commentary: COVID-19 disease is more than just a respiratory infection
por: Ahuja, Ashish, et al.
Publicado: (2021)

Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change
por: de Vet, Henrica C, et al.
Publicado: (2006)

Are we sedating more than just the brain?
por: Brummel, Nathan E, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mg2kfe848ur669rt65u5ur0m2v